Treatment | Day of treatment or re-infestation | ||||||
---|---|---|---|---|---|---|---|
0 | 7 | 14 | 21 | 28 | 35 | ||
Placebo | Range | 4–20 | 13–33 | 7–27 | 11–34 | 15–36 | 5–26 |
A. mean | 12.4 | 21.5 | 20.1 | 20.9 | 26.9 | 18.4 | |
G. mean2 | 11.2a | 20.5a | 18.9a | 19.5a | 25.7a | 16.6a | |
Sarolaner | Range | 0–16 | 9–22 | 9–18 | 10–23 | 8–34 | 12–28 |
A. mean | 3.8 | 15.0 | 12.6 | 16.9 | 16.9 | 18.4 | |
Efficacy (%) | 69.7 | 30.2 | 37.3 | 19.2 | 37.2 | 0.0 | |
G. mean2 | 1.9b | 14.4a | 12.4a | 16.2a | 15.5b | 17.6a | |
Efficacy (%) | 82.8 | 29.6 | 34.4 | 17.0 | 39.6 | 0.0 | |
P-value vs. placebo | <0.0001 | 0.1392 | 0.0791 | 0.4291 | 0.0338 | 0.8025 | |
Afoxolaner | Range | 0–15 | 8–27 | 8–21 | 9–25 | 8–41 | 12–21 |
A. mean | 6.2 | 17.7 | 13.7 | 16.7 | 21.8 | 17.5 | |
Efficacy (%) | 50.2 | 17.8 | 32.1 | 20.2 | 18.8 | 4.8 | |
G. mean2 | 4.1b | 16.4a | 12.6a | 15.4a | 18.9a,b | 16.8a | |
Efficacy (%) | 63.9 | 20.1 | 33.2 | 21.3 | 26.6 | 0.0 | |
P-value vs. placebo | 0.0008 | 0.4068 | 0.1427 | 0.3790 | 0.2500 | 0.9633 | |
P-value vs. sarolaner | 0.0657 | 0.6850 | 0.9533 | 0.8665 | 0.5317 | 0.8806 |